LegoChem Bio signs ADC research license agreement with Takeda

Published: 2017-01-13 08:53:26

Updated: 2017-01-13 08:53:26

LegoChem Biosciences(hereinafter referring to LegoChem Bio) announced it signed a ADC(antibody-drug ) research license agreement with Takeda on the 11^th of January. This is the first license agreement with a global pharmaceutical company in the ADC field.

Under the agreement, the two companies plan to discover a ADC substance candidate using the next-generation ADC platform technology, ConjuAl...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.